May 8, 2018 / 1:58 PM / 16 days ago

BRIEF-Nektar Therapeutics Announces Initiation Of Phase 1B Clinical Study Of NKTR-358

May 8 (Reuters) - Nektar Therapeutics:

* NEKTAR THERAPEUTICS ANNOUNCES INITIATION OF A PHASE 1B CLINICAL STUDY OF NKTR-358, A FIRST-IN-CLASS REGULATORY T CELL STIMULATOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below